Litfulo (ritlecitinib) / Pfizer - LARVOL DELTA

Pediatric Alopecia Areata and JAK Inhibitors: Bridging the Gap Between Evidence and Practice. (PubMed, J Am Acad Dermatol) - "Despite this, emerging evidence and clinical experience demonstrate meaningful hair regrowth in pediatric patients treated with several JAKis, including abrocitinib, baricitinib, deuruxolitinib, ritlecitinib, ruxolitinib, tofacitinib, and upadacitinib, with generally favorable safety profiles. Limitations include heterogeneous outcome reporting between various reports and studies. Overall, this clinical review synthesizes current evidence and clinical experience to provide practical guidance on JAKi selection, dosing, safety monitoring, and key considerations for implementing these therapies in pediatric AA."

Journal • Review • Alopecia • Eosinophilia • Gastrointestinal Disorder • Immunology • Pediatrics

From pathogenesis to emerging therapeutic targets (EADV 2026) - "The lecture will review the rapidly evolving landscape of Janus kinase (JAK) inhibitors, including ruxolitinib, upadacitinib, povorcitinib, baricitinib, and ritlecitinib, with discussion of available phase 2 and phase 3 clinical trial data, combination strategies with phototherapy, and practical considerations for daily clinical practice. - Review the current evidence and clinical development of targeted therapies, particularly JAK inhibitors and novel immune-modulating agents. - Explore the rationale and clinical potential of combination therapies, including JAK inhibitors with phototherapy."

Dermatology • Genetic Disorders • Immunology • Non-melanoma Skin Cancer • Skin Cancer • Solid Tumor • Vitiligo • CAT • CXCL10 • CXCL9 • IFNG • IL15 • NKG2D

Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data (clinicaltrials.gov) - P=N/A | N=7500 | Active, not recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Real-world evidence • Alopecia • Dermatology • Immunology

Effectiveness and Safety of Baricitinib and Ritlecitinib in Severe Alopecia Areata: A Real-World Monocentric Study (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Alopecia • Immunology

Real-World Effectiveness and Safety of Ritlecitinib in Moderate-to-Severe Alopecia Areata: A Tertiary Referral Center Cohort (EADV 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Alopecia • Immunology

Real World Effectiveness of Ritlecitinib in Alopecia Areata: Interim Findings from the PRESTO Prospective Non Interventional Study (EADV 2026) - No abstract available

Clinical • Observational data • Real-world • Real-world effectiveness • Real-world evidence • Alopecia • Immunology

Sequential JAK Inhibition in Severe Alopecia Areata: Sustained Remission After Direct Switch from Tofacitinib to Ritlecitinib (EADV 2026) - No abstract available

Clinical • Alopecia • Immunology

A Multi-Centre Real-World Evaluation of Ritlecitinib in Severe Alopecia Areata: Safety and Treatment Persistence: Efficacy in Skin of Colour (EADV 2026) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Alopecia • Immunology

Predictors of Treatment Response to Ritlecitinib: The Impact of Prior Systemic Therapy and DCP Exposure in Severe Alopecia Areata (EADV 2026) - No abstract available

Alopecia • Immunology

Intraclass Switching of Janus Kinase Inhibitors in Severe Pediatric Alopecia Areata: Two Cases with Favorable Response to Ritlecitinib (EADV 2026) - No abstract available

Clinical • Alopecia • Immunology • Pediatrics

Ritlecitinib as Salvage Therapy in Long-Standing Alopecia Areata With Prior JAK Inhibitor Failure (EADV 2026) - No abstract available

Alopecia • Immunology

Concomitant Alopecia Areata and Scalp Psoriasis Responsive to Ritlecitinib: A Case Supporting Shared JAK-Dependent Inflammatory Pathways (EADV 2026) - No abstract available

Clinical • Alopecia • Dermatology • Immunology • Psoriasis

Real-World Comparison of Ritlecitinib 50 mg and Baricitinib 4 mg in Alopecia Areata: A Retrospective Cohort Study (EADV 2026) - No abstract available

Real-world • Real-world evidence • Retrospective data • Alopecia • Immunology

Switching to ritlecitinib in alopecia areata: Real-world outcomes according to prior JAK inhibitor exposure (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Alopecia • Immunology

Ritlecitinib in middle to severe alopecia areata with eyebrow and eyelash involvement: a single-center, longitudinal real-world outcomes (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Alopecia • Immunology

Comparative real-world effectiveness and safety of baricitinib and ritlecitinib in severe alopecia areata: a 52-week monocentric real-world cohort study (EADV 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Alopecia • Immunology

Topical Ritlecitinib for Refractory Stable Non-Segmental Vitiligo: A Prospective Pilot Study (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Vitiligo

Efficacy and patient characteristics of ritlecitinib in non-responders (SALT score >20) and responders (SALT score ≤20) at Month 36 in patients with alopecia areata from the ALLEGRO clinical trial program (EADV 2026) - No abstract available

Clinical • Alopecia • Immunology

Exploring fingernail involvement in alopecia areata and efficacy of ritlecitinib: a post-hoc analysis in patients from the ALLEGRO trials (EADV 2026) - No abstract available

Clinical • Retrospective data • Alopecia • Immunology

Efficacy and safety of ritlecitinib in patients with nonsegmental vitiligo (NSV): results from the Tranquillo 2 Part Ia and Tranquillo Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trials (EADV 2026) - No abstract available

Clinical • Late-breaking abstract • P3 data • Dermatology • Immunology • Vitiligo

Long-term efficacy of ritlecitinib in patients with alopecia areata and ≥25% scalp hair loss by severity: results from the phase 3 long-term ALLEGRO-LT study through 5 years (EADV 2026) - No abstract available

Clinical • Late-breaking abstract • P3 data • Alopecia • Immunology

ALLEGRO-100: A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata (clinicaltrials.gov) - P3 | N=674 | Recruiting | Sponsor: Pfizer | N=1330 ➔ 674

Enrollment change • Alopecia • Dermatology • Immunology

Calcitonin gene-related peptide promotes mast cell-mediated neuroimmune inflammation through the CALCRL/RAMP1-JAK3-STAT1 axis in rosacea. (PubMed, Front Immunol) - "Rimegepant or ritlecitinib attenuated CGRP-induced JAK3-STAT1 activation and mast-cell responses. These findings identify a CGRP-associated neuroimmune pathway in rosacea in which CALCRL/RAMP1-linked JAK3-STAT1 signaling promotes mast cell-mediated inflammatory amplification. Targeting the CGRP-CALCRL/RAMP1-JAK3-STAT1 axis may provide a mechanism-based therapeutic strategy for neurovascular-dominant or treatment-refractory rosacea."

Journal • Dermatology • Inflammation • Rosacea • CALCRL • JAK3 • KIT • STAT1

Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data (clinicaltrials.gov) - P=N/A | N=7500 | Not yet recruiting | Sponsor: Pfizer

New trial • Real-world evidence • Alopecia • Dermatology • Immunology

Long-term real-world effectiveness of ritlecitinib and baricitinib in children and adolescents with alopecia areata: a 24-month retrospective study. (PubMed, Clin Exp Dermatol) - No abstract available

Journal • Real-world evidence • Retrospective data • Alopecia • Immunology